Claims for Patent: 11,129,896

Summary for Patent: 11,129,896

Title:	Topical formulations and treatments
Abstract:	Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.
Inventor(s):	Alur; Hemant H. (Basking Ridge, NJ), Harwick; James A. H. (Tallassee, AL)
Assignee:	Trilogic Pharma LLC (Tallassee, AL)
Application Number:	15/746,012
Patent Claims:	1. A method of treating bacterial vaginosis in a patient in need thereof, comprising: administering only once to the patient over a period of from 8 to 29 days a therapeutically effective amount of a pharmaceutical gel formulation including: (i) from 70 to 90 weight parts of water; (ii) from 10 to 25 weight parts of a copolymer having the following block structure: HO--[CH.sub.2--CH.sub.2--O].sub.a--[CH.sub.2--CH(CH.sub.3)--O].sub.b--[CH- .sub.2--CH.sub.2--O].sub.a--H wherein the ratio of a:b is from 2:1 to 4:1 and, when a and b are summed, the molecular weight of said copolymer is from 9000 to 16000; (iii) from 0.5 to 3.0 weight parts of xanthan gum; and (iv) from 1.0 to 4.0 weight parts of clindamycin phosphate based on the weight of the free base of clindamycin. 2. The method of claim 1, wherein the formulation includes an amount of clindamycin phosphate equivalent to from 1.0 to 2.0 weight parts of the free base. 3. The method of claim 1, wherein the pharmaceutical formulation further includes from 0.5 to 1.5 weight parts of benzyl alcohol. 4. The method of claim 1, wherein the pharmaceutical formulation further includes from 25 to 100 mM of a citrate buffer. 5. The method of claim 1, wherein the pharmaceutical formulation includes from 70 to 80 weight parts of water. 6. The method of claim 1, wherein the pharmaceutical formulation includes from 10 to 20 weight parts of said copolymer. 7. The method of claim 1, wherein said copolymer is poloxamer. 8. The method of claim 1, wherein a sum of a's in the block structure of the copolymer equals 200, and b in the block structure has a value of 65. 9. The method of claim 1, wherein the pharmaceutical formulation includes from 1.5 to 2.5 weight parts of said xanthan gum. 10. The method of claim 1, wherein the pharmaceutical formulation has a gel temperature that is between room temperature and the body temperature of said patient. 11. The method of claim 1, wherein the pharmaceutical formulation has a viscosity at room temperature of from 100,000 to 1,000,000 centipoise. 12. The method of claim 1, wherein the pharmaceutical formulation contains no other component that changes the viscosity of said formulation at room temperature by more than 100,000 centipoise. 13. The method of claim 1, further comprising releasing a therapeutically effective amount of said clindamycin phosphate from said formulation over a period of from 1 to 21 days. 14. The method of claim 1, wherein said pharmaceutical formulation is administered only once to the patient over a period of from 8 to 15 days. 15. The method of claim 1, wherein the formulation has a gel temperature that is between room temperature (22.degree. C.) and body temperature (37.degree. C.). 16. The method of claim 1, wherein the formulation has from 1.5 to 2.5 weight parts of xanthan gum.